Human Herpesvirus 6B U26 Inhibits the Activation of the RLR/MAVS Signaling Pathway

Xuefeng Jiang1, Tian Tang1, Jinfeng Guo1

  • 1Department of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.

Mbio
|February 17, 2021
PubMed

Insights

Human herpesvirus 6B (HHV-6B) U26 protein is crucial for viral replication by inhibiting the host

Area of Science:

  • Virology
  • Immunology
  • Molecular Biology

Background:

  • Human herpesvirus 6B (HHV-6B) establishes lifelong infections and evades host immunity.
  • The function of the unique HHV-6B gene U26 remains largely unknown.
  • Understanding HHV-6B immune evasion strategies is critical for developing therapies.

Purpose of the Study:

  • To elucidate the function of the HHV-6B U26 protein during viral infection.
  • To investigate the role of U26 in host innate antiviral immune responses.
  • To identify potential therapeutic targets for HHV-6B infection.

Main Methods:

  • Gene knockdown experiments to assess U26's role in viral production.
  • Analysis of the retinoic acid-inducible gene I (RIG-I)-like receptor (RLR)/mitochondrial antiviral signaling protein (MAVS) pathway activation.
  • Mitochondrial localization studies and membrane potential assays.

Main Results:

  • HHV-6B U26 is expressed early in infection and is essential for progeny virus production.
  • U26 inhibits the RLR/MAVS signaling pathway by promoting MAVS protein degradation.
  • U26 localizes to mitochondria, impacting membrane potential and facilitating MAVS degradation.

Conclusions:

  • HHV-6B U26 acts as a novel viral antagonist against host innate immunity.
  • U26's inhibition of the RLR/MAVS pathway is key to HHV-6B's immune evasion.
  • Targeting U26 or the MAVS pathway could offer new therapeutic strategies against HHV-6B.